Trials / Active Not Recruiting
Active Not RecruitingNCT05038228
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF with high risk of gastrointestinal bleed who initiate anticoagulant treatment with a Vitamin-K Antagonists (VKAs) or direct-acting oral anticoagulants (DOACs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Anticoagulant |
| DRUG | Rivaroxaban | Anticoagulant |
| DRUG | Dabigatran | Anticoagulant |
| DRUG | Vitamin K antagonist (VKA) | Anticoagulant |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2026-04-08
- Completion
- 2026-04-08
- First posted
- 2021-09-09
- Last updated
- 2026-03-12
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05038228. Inclusion in this directory is not an endorsement.